Danielle Loewenstein

Danielle Loewenstein is a highly educated professional with a diverse academic background. She holds a magna cum laude Bachelor of Laws (LL.B.) and Master of Laws (LL.M.) in Commercial Law from Tel Aviv University. Additionally, she has a Bachelor of Arts (BA), magna cum laude, in East Asian Studies from the same university. Furthermore, she earned her Master of Business Administration (MBA) from the prestigious Harvard Business School. Danielle also completed the HMX Fundamentals online program in Immunology at Harvard Medical School.

In terms of her professional experience, Danielle Loewenstein is currently serving as the Head of Pharma Research and Early Development Business Development Finance at Genentech, a well-known biotechnology company acquired by Roche. Prior to her current role, she held the position of R&D Business Development Finance at Genentech. She also has experience in Investor Relations at Roche and has worked as an FRDP Associate as well as an MBA Finance Intern at Genentech. Earlier in her career, Danielle served as an Attorney at S. Horowitz & Co., showcasing her legal expertise. Moreover, she has a background as an Intelligence Officer at Unit 8200 in the IDF, which highlights her strategic and analytical skills.

Danielle Loewenstein's academic achievements and extensive professional background demonstrate her expertise in law, business administration, and finance. Her experience in the pharmaceutical industry, particularly in research and development, positions her as a valuable asset in the field of healthcare and biotechnology. With a blend of legal, financial, and strategic competencies, Danielle brings a unique perspective to her current role as Head of Pharma Research and Early Development Business Development Finance at Genentech.